treatment-resistant depression
A New Dawn for Psychedelics: Compass Pathways Nears Major Phase 3 Psilocybin Results
Compass Pathways; COMP360; psilocybin; treatment-resistant depression; phase 3 trial; psychedelic therapy; FDA Breakthrough Therapy; mental health innovation
Supernus Pharmaceuticals’ Depression Drug SPN-820 Fails to Meet Primary Endpoint in Phase 2b Trial
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, Phase 2b trial, clinical study failure, MADRS score, placebo effect
Supernus Pharmaceuticals’ Stock Plummets as Phase 2b Depression Drug Trial Fails to Meet Primary Endpoint
Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, clinical trial failure, stock decline, placebo effect
GH Research Reports Positive Phase 2b Results for Inhaled 5-MeO-DMT in Treatment-Resistant Depression
GH Research, 5-MeO-DMT, GH001, treatment-resistant depression, psychedelic therapy, clinical trial, Phase 2b